Skip to main content

Table 1 Demographic and clinical data of people with Parkinson’s disease and controls

From: LSVT-BIG therapy in Parkinson’s disease: physiological evidence for proprioceptive recalibration

  All PwPD
(n = 30)
BIG
(n = 11)
Controls
(n = 15)
Age (years) 64.8 ± 7.3 69.8 ± 6.1 65.0 ± 5.6
Sex (female/male) 10/20 3/8 10/5
LED (mg) 614 ± 394 518 ± 295 $ N/A
FD (years) 4.6 ± 3.9 3.6 ± 2.5 N/A
UPDRS III (at baseline) a 18 [12 to 24] 23 [12 to 25] N/A
Handedness (right/ ambidextrous/left) 26/4/0 8/3/0 15/0/0
PANDA (normal/MCI/ dementia likely) 24/2/4 8/1/2 14/1/0
FAB (frontal impair-ment: yes/no) 0/30 0/11 0/15
  1. PwPD people with Parkinson’s disease, LED Levodopa Equivalent Dose ($ no significant LED change over the time period of investigation), FD first diagnosis, UPDRS III motor subscale of the MDS Unified Parkinson’s Disease Rating Scale, PANDA Parkinson Neuropsychometric Dementia Assessment, MCI mild cognitive impairment, FAB Frontal Assessment Battery, N/A not applicable
  2. a = given as median (range)